Trimethobenzamide FDA Alerts
The FDA Alerts below may be specifically about trimethobenzamide or relate to a group or class of drugs which include trimethobenzamide.
MedWatch Safety Alerts are distributed by the FDA and published by Drugs.com. Following is a list of possible medication recalls, market withdrawals, alerts and warnings.
Recent FDA Alerts for trimethobenzamide
Trimethobenzamide hydrochloride suppositories
[Posted 04/06/2007] FDA notified healthcare professionals and consumers that companies must stop manufacturing and distributing unapproved suppository drug products containing trimethobenzamide hydrochloride. These products are used to treat nausea and vomiting in adults and children. The products have been marketed under various names, including Tigan, Tebamide, T-Gen, Trimazide, and Trimethobenz. Drugs containing trimethobenzamide in suppository form lack evidence of effectiveness. This action does not affect oral capsules and injectable products containing trimethobenzamide that have been approved by FDA. FDA urges consumers currently using trimethobenzamide suppositories or who have questions or concerns to contact their healthcare professional. Alternative products approved to effectively treat nausea and vomiting are available in a variety of forms.[April 6, 2007 - News Release - FDA]
More trimethobenzamide resources
- Trimethobenzamide oral/injection Consumer Information
- Arrestin Advanced Consumer Information
- Stemetic Advanced Consumer Information
- Tribenzagan Advanced Consumer Information
- Trimethobenzamide (Intramuscular) Advanced Consumer Information
- Trimethobenzamide (Oral) Advanced Consumer Information
- Trimethobenzamide AHFS DI Monograph
- Trimethobenzamide Capsules Consumer Information
- Tigan Injection Prescribing Information
- Trimethobenzamide Capsules Prescribing Information
